Page 2500 - Hematology_ Basic Principles and Practice ( PDFDrive )
P. 2500

2232   Part XIII  Consultative Hematology


                                                              predominantly case reports in the pediatric literature, in one review
         Treatment of Immune-Mediated Thrombocytopenia After Solid Organ
         Transplant in Children                               of neutropenia after 400 renal transplants in adults, 35 cases (9%)
                                                                         365
                                                              were reported.  The etiology of leukopenia or neutropenia is similar
          There is no standard approach to the treatment of immune-mediated   in children and adults and includes immunosuppressive agents; other
          thrombocytopenia  that  occurs  after  solid  organ  transplant.  First,  all   myelosuppressive  drugs  (e.g.,  ganciclovir);  infection  (e.g.,  CMV,
          other causes of thrombocytopenia should be ruled out before beginning   sepsis); and, less frequently, INF, PTLD, hypersplenism, and idio-
          therapy for what is often a presumptive diagnosis of immune-mediated   pathic.  Use  of TAC  is  often  implicated  as  a  possible  contributing
          thrombocytopenia.  If  the  thrombocytopenia  is  mild  to  moderate   factor.
          (>20,000  to  30,000/µL)  with  no  associated  bleeding  symptoms,  we   Both filgrastim (granulocyte colony-stimulating factor) and sar-
          usually  observe  without  intervention  and  monitor  the  platelet  count   gramostim (granulocyte macrophage colony-stimulating factor) have
          on at least a weekly basis. If the platelet count is less than 10,000 to   been used to treat neutropenia in adults and children. In adults, it
          15,000/µL or if there is bleeding, immediate treatment is initiated with
          high-dose corticosteroids: 4 mg/kg/day of prednisone (or intravenous   has resulted in improvement of the WBC count in more than 90%
                                                                                         365,366
          equivalent) divided into three or four doses and continued for 4 days. If   of patients after three or four doses.   There was no evidence of
          there is a response (i.e., platelet count >20,000/µL), the corticosteroid   precipitation of rejection. In the case reports of children, both agents
          is dropped to 2 mg/kg/day divided into two or three doses and then   have been found to be effective in most patients, but there is a sug-
          slowly tapered to zero over the subsequent 2 to 3 weeks. Intravenous   gestion that efficacy may be affected by continuation of TAC. 364,367,368
          immunoglobulin or anti-RhD in standard doses for childhood idiopathic   Although cytokine therapy has been shown to increase the neutrophil
          thrombocytopenic  purpura  can  be  used  if  there  is  no  response  to   count, there is insufficient data to prove the effectiveness of prevent-
          high-dose corticosteroids.                          ing or treating infection or decreasing mortality. 369
           For  patients  who  have  recurrent  or  chronic  thrombocytopenia   There has been one report on the use of granulocyte transfusions
          requiring  multiple  courses  of  treatment  to  maintain  platelet  counts
          greater than 10,000 to 15,000/µL, we have used vincristine (1.5 mg/  in solid organ transplant recipients, including one child. Of the 14
           2
          m   [maximum  dose,  2 mg]  intravenously  weekly  for  6  weeks)  with   patients studied, 11 showed an increase in ANC greater than 1000/µL
          success.  Rituximab  (375 mg/m   intravenously  weekly  for  4  weeks)   by the end of the course. Of 12 patients with infections, 4 (33%)
                                2
          has  infrequently  been  used  in  this  situation.  For  patients  taking   showed a clinical response. Additional studies are needed to evaluate
          tacrolimus  with  refractory  thrombocytopenia,  serious  consideration   the efficacy of granulocyte transfusions in transplant patients. 369
          should  be  given  to  switching  to  an  alternative  immunosuppressant   Azathioprine is well known to cause myelosuppression and has
          drug  because  this  may  be  necessary  for  resolution  of  the  throm-  been associated with moderate to severe neutropenia. Azathioprine is
          bocytopenia.  Involvement  of  both  the  transplant  team  and  the   catabolized in vivo by xanthine oxidase and thiopurine methyltrans-
          hematology team is necessary for ideal management of these complex    ferase (TPMT). TPMT activity can vary considerably depending on
          patients.
                                                              a genetic polymorphism. Approximately 0.3% of white persons are
                                                              homozygous  and  11%  are  heterozygous  for  deficiency  of  TPMT.
                                                              Severe myelosuppression, including fatal neutropenia, has been docu-
                                                              mented  in  transplant  patients  who  are  homozygous  for  TMPT
                                                                                           370
        and  one  patient’s  thrombocytopenia  resolved  after  an  episode  of   deficiency  and  receiving  azathioprine.   Some  data  suggest  that
        severe  graft  rejection  (see  box  on Treatment  of  Immune-Mediated   monitoring  6-thioguanine  nucleotides  (the  metabolites  of  azathio-
        Thrombocytopenia After Solid Organ Transplant in Children).  prine)  may  allow  for  individualized  management  of  azathioprine
                                                              dosing with fewer side effects, although this has not become common
                                                                    371,372
        Infection-Associated Thrombocytopenia                 practice.
                                                                 Neutropenia has also been associated with the use of MMF and
        Posttransplant                                        sirolimus.  Neutropenia  and  thrombocytopenia  have  been  noted  as
                                                                                     373
                                                              side effects of MMF since 1998.  Leukopenia may affect 5% to 11%
        Although there are few published reports, one would expect the same   of patients taking the drug, and pseudo Pelger-Huet anomaly has also
        hematologic problems, including thrombocytopenia, associated with   been noted. 374,375  The leukopenia is often seen within 2 to 8 months
        bacterial sepsis or other serious infections as seen in nontransplant   after starting the drug. Filgrastim has been effective in reversing the
        patients. Infection with HHV-6 and the herpesvirus group has been   neutropenia, although some patients require decreasing the dose or
        studied closely. HHV-6 is commonly seen after transplant, mostly in   stopping the drug. Ganciclovir and valacyclovir are commonly used
        stem cell transplant recipients. In adults after liver transplant, there   simultaneously with MMF to treat or prevent CMV disease. These
                                                                                                       376
        are case reports of a syndrome of HHV-6 infection with thrombocy-  drugs are also known to be associated with neutropenia.  There may
                                   359
        topenia, fever, and encephalopathy.  This syndrome has not been   be  an  interaction  between  these  drugs  that  increases  the  risk  for
        reported in children with HHV-6 infection. 360,361    neutropenia. 377,378  It may be necessary to stop ganciclovir as well as
                                                                                           374
           Herpesvirus infection after kidney transplant in children is seen   MMF for the neutropenia to improve.  Of note, serious infections
        in about one-third of patients, with CMV being the most common   are infrequently encountered.
               362
        infection.  The hematologic abnormalities associated with herpes-  In two reports of the use of sirolimus in children, neutropenia was
        virus  infection  include  thrombocytopenia  and  leukopenia,  with   the most common toxicity, along with hepatitis, hyperlipidemia, and
        incidence  rates  of  31%  and  24%,  respectively.  These  and  other   mouth ulcers. 379,380  It is not clear whether the neutropenia is directly
        symptoms of herpesvirus infection occur at the same frequency as in   related  to  serum  level  of  the  drug.  Most  counts  improve  with  a
        nontransplant patients. There is a case report of a child after liver   decrease in the drug dose, although a few patients need to have the
        transplant  who  developed  measles  complicated  by  autoimmune   drug discontinued.
        thrombocytopenia and neutropenia. 363
                                                              Pancytopenia
        White Blood Cells
                                                              Pancytopenia is seen in two settings after solid organ transplant. The
        Leukopenia and neutropenia after solid organ transplant are uncom-  first is early after liver transplant for acute liver failure from acute
        monly reported in the literature, although this may not reflect the   infectious hepatitis. 381,382  This represents the known aplastic anemia
                               364
        true incidence seen in practice.  Authors of two reviews of hemato-  that can be seen in as many as one-third of patients after non–A-E
        logic  complications  in  children  after  transplant  reported  isolated   hepatitis. Treatment and outcome are similar to those in patients with
        neutropenia in 2 (3%) of 70 patients after liver transplant and 9 (8%)   posthepatitic aplastic anemia who do not require liver transplant. The
        of 106 patients after cardiothoracic transplant. 312,313  Neutropenia was   second setting is delayed pancytopenia, which may be secondary to
                                           331
                                                                                        383
        also seen in combination with other cytopenias.  Although there are   infection with or without PTLD.  A number of cases have been
   2495   2496   2497   2498   2499   2500   2501   2502   2503   2504   2505